Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Staff constraints made it impossibile to enroll consecutive patients, making the sample not representative of the true cancer population
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lung cancer may cause central airway obstruction through several different mechanisms (invasion by the primary tumor, invasion by metastatic lymph nodes, airway metastasis).
The aim of the present study is to determine the prevalence at the time of diagnosis, the incidence at 1 year from the diagnosis, and the predictors of central airway obstruction associated with advanced lung cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lung Cancer | All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of central airway obstruction | The incidence will be measured over a 12 month period after diagnosis (or over the life span from diagnosis to death in patients who die before 1 year from the diagnosis) | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Predictor variables associated with the presence/occurrence of central airway obstruction | 12 months | |
| Prevalence of central airway obstruction | The prevalence of central airway obstruction will be evaluated at the time of diagnosis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with advanced lung cancer undergoing treatment and follow-up at the Oncology Units of the Azienda USL di Bologna (government structure that manages several public hospitals that "cover" a 800.000 inhabitants area)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rocco Trisolini, M.D. | Maggiore Bellaria Hospital, Bologna, Italy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bentivoglio Hospital | Bentivoglio | Emilia-Romagna | 40010 | Italy | ||
| Bellaria Hospital |
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 day |
| Bologna |
| Emilia-Romagna |
| 40100 |
| Italy |
| Maggiore Hospital | Bologna | Emilia-Romagna | 4013 | Italy |
| Budrio Hospital | Budrio | Emilia-Romagna | 40054 | Italy |
| SS Salvatore Hospital | San Giovanni in Persiceto | Emilia-Romagna | 40017 | Italy |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |